The global pathology services market is projected to grow from $212.8 billion in 2024 to $307.9 billion by 2030 at a 6.5% CAGR, driven by rising cancer incidence, digital pathology adoption, and molecular diagnostics expansion. North America leads with 41.2% market share, while AI-enabled platforms are delivering measurable ROI through cost savings and improved efficiency. Large reference laboratory operators are best positioned to capture outsourcing opportunities and scale molecular testing capabilities.

The global blood-based biomarkers market is projected to grow from USD 8.5 billion in 2025 to USD 18.5 billion by 2034, driven by increasing demand for non-invasive diagnostics, rising chronic disease prevalence, and advances in genomics and liquid biopsy technologies. North America leads with 44% market share, while Asia-Pacific shows fastest growth. Key players include Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific.

The global cancer biomarkers market is projected to grow from $25.9 billion in 2026 to $37.8 billion by 2035, with a CAGR of 4.3%. Growth is driven by rising cancer incidence, personalized medicine adoption, advances in NGS and liquid biopsy technologies, and increased biomarker-driven diagnostics. HER2 testing leads by biomarker type (21.1% share), while breast cancer testing dominates by indication (25.1% share). North America captures 52.1% of global market revenue.

A Canadian health coalition has called on Ontario's Health Minister to halt Quest Diagnostics' transfer of laboratory testing services from Ontario hospitals to U.S.-based facilities. The coalition argues that the transfers, which began in April 2026, compromise patient privacy, reduce hospital efficiency, delay results, and divert healthcare funding to the United States. They are demanding the government cancel Quest's contract and restore lab services to public hospital control.

Quest Diagnostics announced a quarterly cash dividend of $0.86 per share, payable on July 22, 2026 to shareholders of record as of July 8, 2026. The diagnostic information services leader serves half of U.S. physicians and hospitals and one in three American adults annually.

The global HPV testing and Pap test market is projected to grow from USD 3.7 billion in 2025 to USD 6.5 billion by 2034, driven by rising cervical cancer prevalence, government screening initiatives, technological advancements, and the introduction of self-sampling tests. North America leads the market with 40.5% share, while Asia-Pacific emerges as a key growth hub.

The global drug screening market is projected to reach USD 20.86 billion by 2031, growing at a CAGR of 16.16%. Chromatography and mass spectrometry technologies dominated with 44.77% market share in 2025. Asia-Pacific is the fastest-growing region, driven by expanding healthcare infrastructure and workplace safety initiatives. Market growth is fueled by increasing adoption across workplaces, healthcare settings, and law enforcement, alongside technological advancements in point-of-care testing and rapid detection devices.

The global genomics services market is expected to grow from USD 7.94 billion in 2025 to USD 25.18 billion by 2035, with a CAGR of 11.8%. Growth is driven by increasing genetic disorder prevalence, government-funded precision medicine initiatives, and rising adoption of NGS-based diagnostics. The U.S. market alone is projected to reach USD 10.04 billion by 2035. Next-generation sequencing dominates with 38.42% market share, while Asia Pacific shows the fastest growth at 13.84% CAGR.

Quest Diagnostics announced a 7.5% increase in its quarterly dividend to $0.86 per share, marking 15 consecutive years of dividend increases. The company also increased its share repurchase authorization by $1 billion, bringing total available repurchase authority to approximately $1.4 billion.

With 59% of S&P 500 companies reported, Q4 2025 shows 13% EPS growth and 8.8% revenue growth. Big Tech's massive capex spending on AI infrastructure ($185B for Alphabet, $200B for Amazon) has sparked concerns about free cash flow sustainability and SaaS disruption from AI agents. This week's earnings focus shifts to semiconductor and software companies to assess whether AI spending benefits the broader ecosystem or threatens traditional business models.

A comprehensive market research report on over-the-counter and direct-to-consumer infectious disease diagnostics forecasts significant growth through 2029, driven by rapid testing technologies, privacy concerns, and digital accessibility. The report analyzes market trends across 15 countries, covering respiratory, STD, UTI, and other infectious disease testing channels, with profiles of 70+ diagnostic companies.

The global esoteric testing market is projected to grow from $27.52 billion in 2025 to $41.56 billion by 2031 at a 7.11% CAGR, driven by rising chronic disease rates, personalized medicine demand, and liquid biopsy adoption. However, stringent regulatory frameworks and reimbursement pressures pose significant challenges to market expansion.